Introduction
In the 1977 survey on drug product selection (DPS) in the state of Florida,' the researcher found that, while 36.3 per cent of all new prescriptions issued in Florida were potentially eligible for product interchange, only 6 .2 per cent of the eligible prescriptions were actually interchanged. Since the survey was conducted approximately one year after the enactment of Florida's Drug Product Selection Law,2 the low rate of product interchange may have been due in part to a need for a longer period of time for pharmacists, physicians, and consumers to adapt their behaviors to conform to the intent and specific provisions of the new law.
The purpose of the present study was to assess the longterm effects of Florida's Drug Product Selection Law on product selection and brand interchange. In assessing these effects it should be noted that, although the patient has the opportunity to prohibit DPS, pharmacists are not required under the terms of the Florida law to make any notation when patient refusal occurs.
Methods
In the 1977 survey, a stratified random sample of 60 Florida community pharmacies (3 per cent of total) were selected from a list of all community pharmacies obtained from the Department of Professional and Occupational Regulation. Resurvey approval was obtained from 52 (85 per cent) of these original pharmacies, hence the comparisons across studies could be somewhat biased by the fact that all of the original 60 pharmacies were not resurveyed.
The data collection process used in 1977 was repeated. Every effort was made to obtain the actual acquisition costs of both the products prescribed and the products dispensed. This was usually accomplished by looking at vouchers dated closest to the prescription filling date. In addition, the sampling frame was expanded from four months to a year to determine if there were any seasonal differences in the DPS rates. No such differences were found, however.
Results
The prescribing behaviors of Florida physicians during the two study periods are compared in Table 2 displays the comparisons for mean price of products prescribed, mean price of products dispensed, and mean reduction in retail price. The consumer did save an average of $2.40 per prescription when product selection took place, but this increase over the average savings determined in 1977 also was not significant. The savings passed on to the consumer represented over 90 per cent of the reduction in acquisition costs of the dispensing pharmacies. Some caution must be used in interpreting savings based on acquisition costs as invoices could not always be verified. Also, acquisition costs obtained at the individual pharmacy level could be higher than those actually paid by the small and large chain pharmacies.
With the above cautions in mind, it was estimated that prescription purchasers statewide saved approximately $3,800,000 during the 1979-80 study through drug product selection. This figure was determined by applying the DPS rate and the reduction in retail price determined in the sample pharmacies to all new prescriptions dispensed in the state during the study period. The actual savings may have Pharmacists, on the other hand, appeared to be reluctant to engage in brand interchange without explicit permission from the prescriber. Even though the Florida law is considered mandatory, and each pharmacy is responsible for compiling its own positive formulary, no sanctions for noncompliance were included in the law at the time of this study.
A recent study indicated that states with positive formularies had higher substitution rates than those without them; and formularies that were state generated were more effective in encouraging substitution than the Food and Drug Administration's formulary.4
